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Abstract: A field study was undertaken to (i) measure the prevalence of feline leukaemia virus (FeLV)
exposure and FeLV infection in a cross-section of healthy Australian pet cats; and (ii) investigate the
outcomes following natural FeLV exposure in two Australian rescue facilities. Group 1 (n = 440)
consisted of healthy client-owned cats with outdoor access, predominantly from eastern Australia.
Groups 2 (n = 38) and 3 (n = 51) consisted of a mixture of healthy and sick cats, group-housed in
two separate rescue facilities in Sydney, Australia, tested following identification of index cases of
FeLV infection in cats sourced from these facilities. Diagnostic testing for FeLV exposure/infection
included p27 antigen testing using three different point-of-care FeLV kits and a laboratory-based
ELISA, real-time polymerase chain reaction (qPCR) testing to detect FeLV proviral DNA in leukocytes,
real-time reverse-transcription PCR (qRT-PCR) testing to detect FeLV RNA in plasma, and neutralising
antibody (NAb) testing. Cats were classified as FeLV-uninfected (FeLV-unexposed and presumptively
FeLV-abortive infections) or FeLV-infected (presumptively regressive and presumptively progressive
infections). In Group 1, 370 FeLV-unexposed cats (370/440, 84%), 47 abortive infections (47/440, 11%),
nine regressive infections (9/440, 2%), and two progressive infections (2/440, 0.5%) were identified, and
12 FeLV-uninfected cats (12/440, 3%) were unclassifiable as FeLV-unexposed or abortive infections due
to insufficient samples available for NAb testing. In Groups 2 and 3, 31 FeLV-unexposed cats (31/89,
35%), eight abortive infections (8/89, 9%), 22 regressive infections (22/89; 25%), and 19 progressive
infections (19/89; 21%) were discovered, and nine FeLV-uninfected cats (9/89; 10%) were unclassifiable
due to insufficient samples available for NAb testing. One of the presumptively progressively-infected
cats in Group 3 was likely a focal FeLV infection. Two other presumptively progressively-infected
cats in Group 3 may have been classified as regressive infections with repeated testing, highlighting
the difficulties associated with FeLV diagnosis when sampling cats at a single time point, even with
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results from a panel of FeLV tests. These results serve as a reminder to Australian veterinarians
that the threat of FeLV to the general pet cat population remains high, thus vigilant FeLV testing,
separate housing for FeLV-infected cats, and FeLV vaccination of at-risk cats is important, particularly
in group-housed cats in shelters and rescue facilities, where outbreaks of FeLV infection can occur.
Keywords: veterinary science; feline leukaemia virus; FeLV diagnosis; antigen testing; PCR;
cats; Australia
1. Introduction
In many countries, the prevalence of feline leukaemia virus (FeLV) infection in domestic cats
has decreased since the 1970s and 1980s [1,2]. For example, in parts of Australia, Europe, and North
America, prevalence rates of 1–6% have been reported in the past decade [3–6]. This decrease has
been attributed to veterinary interventions, including rigorous testing combined with vaccination, and
isolation or euthanasia of infected animals [2,7]. The implementation of biosecurity protocols, with
or without concurrent vaccination, has effectively protected group-housed cats [2,8]. Nevertheless,
studies have demonstrated that progressive FeLV infections remain common in some regions, such
as Southeast Asia and Brazil, where the prevalence is 12–25% [9–13], and recently in Australia a
prevalence of 13% (72/563) was reported, with the majority of infections identified in sick cats tested
as part of routine diagnostic investigations [14]. This finding highlights that the possibility of FeLV
infection should still be considered by Australian veterinarians. Indeed, the risk of FeLV infection
remains sufficiently high in the general cat population that current guidelines recommend shelter staff
test all incoming cats of unknown retroviral status for FeLV infection following a six-week quarantine
period [8].
The pathogenesis of FeLV infection varies according to the host immune response. The main host
outcomes following FeLV exposure are complete elimination of FeLV following an effective immune
response (‘abortive infection’), a partially effective immune response that clears the viraemia but
does not prevent proviral integration (‘regressive infection’), and persistent viraemia with proviral
integration (‘progressive infection’) [2,15–18]. To differentiate between these outcomes, antigen testing
(to detect viral capsid protein p27), polymerase chain reaction (PCR) testing (to detect proviral DNA),
reverse-transcription (RT)-PCR testing (to detect viral RNA [vRNA]), and testing for antibodies against
FeLV are required [16]. Progressively-infected cats have the poorest prognosis, with reported mortality
rates of up to 90% within three years of infection, predominantly due to aplastic anaemia, lymphoma,
leukaemia, or other myeloproliferative diseases [2,15,16,19,20]. Although the role of regressive FeLV
infection in disease causation is not clear, an association between regressive infections and lymphoma
has been observed in Australia and Canada [21–23]. It is important to identify FeLV infections and to
differentiate regressive versus progressive infections, to guide prognosis for the individual cat and to
direct clinical management.
The aims of the current study were to (i) measure the prevalence of FeLV exposure and FeLV
infection in a cross-section of healthy Australian pet cats; and (ii) investigate the outcomes following
natural FeLV exposure in two Australian rescue facilities.
2. Materials and Methods
2.1. Study Population
Three groups of cats in Australia, together comprising 529 cats, were included (Figure 1):
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Figure 1. Map of Australia, showing the location of the veterinary hospitals (Group 1; blue dots) used
to recruit cats from all Australian States and Territories except WA, NT, and TAS, and the location of
the two rescue facilities in Sydney, NSW (Groups 2 and 3; red dots). An enlargement of Sydney and
its surrounding areas is shown in the breakout box. The grey shading in the breakout box represents
the ‘Built Up Areas’ of Sydney (as defined by Geosciences Australia, http://www.ga.gov.au/mapspecs/
250k100k/appendixA_files/Habitation.html#Habitation Built Up Area Polygon) and is included to
show the semi-rural location of the two rescue facilities and one veterinary hospital on the outskirts of
Sydney. ACT = Australian Capital Territory, NSW = New South Wales, NT = Northern Territory, QLD
= Queensland, SA = South Australia, TAS = Tasmania, VIC = Victoria, WA = Western Australia.
(i) Group 1 (n = 440) consisted of client-owned cats predominantly living in eastern Australia
that were part of a case-control study investigating the effectiveness of a commercially available
feline immunodeficiency virus (FIV) vaccine (Fel-O-Vax FIV®, Boehringer Ingelheim, Fort Dodge, IA,
USA) [24]. Cats included in the current study were at least two years-of-age (according to veterinary
hospital records), had outdoor access (since cats housed exclusively indoors are not exposed to FIV and
FeLV unless cohabiting with an already infected cat), and had no clinical signs of illness [25]. Eleven
cats that were excluded from the original study investigating the effectiveness of the FIV vaccine, as
they had previous but not current outdoor exposure at the time of sampling, and did not fit the strict
criteria for the case-control model, were included in the current study since they had previously been
allowed outdoor access and therefore were deemed to have potentially been exposed to FeLV [24].
Complete vaccination histories were available for these cats: 145/440 (33%) had been vaccinated
against FeLV, comprising 90/145 (62%) that had been vaccinated within the previous 12 months (i.e.,
‘on-time’ according to the manufacturers’ guidelines) and 55/145 (38%) that had been vaccinated >12
months (‘overdue’ for vaccination). Cats had been vaccinated with one of three FeLV vaccines (36 with
Fel-O-Vax Lv-K®, Boehringer Ingelheim, Fort Dodge, IA, USA; 108 with Fel-O-Vax F5®, Boehringer
Ingelheim, Fort Dodge, IA, USA; one with Leucogen®, Virbac Animal Health, Carros, France).
(ii) Group 2 (n = 38) consisted of asymptomatic and sick cats group-housed in a rescue facility
near Sydney, Australia. This facility was an occupied house located in a semi-rural area, with all cats
allowed to roam freely during the day. Some of the more tractable cats were group-housed indoors
at night. The ages of cats were recorded when available, based on their known history or estimates
provided by their regular veterinarian. The age of one cat was unknown. None of the cats had been
vaccinated against FIV or FeLV.
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(iii) Group 3 (n = 51) consisted of asymptomatic and sick cats group-housed in another rescue
facility near Sydney, Australia (35 km from Group 2; no cats transferred between the two facilities). This
facility was an occupied house located in a semi-rural area, with all cats permanently group-housed
either indoors or outdoors in large walk-through enclosures. The ages of cats were recorded when
available; the ages of 41 cats were unknown. None of the cats had been vaccinated against FIV or FeLV.
Animal ethics approval for the sampling of cats in Group 1 was granted by the University of
Sydney (UoS) Animal Ethics Committee (Approval number N00/1-2013/3/5920). Cats in Groups 2 and 3
were sampled and tested at the request of the facility managers following the diagnosis of progressive
FeLV infections (A.H. and M.P., respectively).
2.2. Determination of FeLV Exposure/Infection Status
Diagnostic testing undertaken included p27 testing with three different point-of-care (PoC) FeLV
antigen kits, p27 testing with a laboratory-based non-proprietary ELISA (in use since before PoC FeLV
testing became available), semi-quantitative real-time proviral PCR (qPCR) testing to detect FeLV
proviral DNA in leukocytes, semi-quantitative qRT-PCR testing to detect FeLV RNA in plasma, and
testing for anti-FeLV neutralising antibodies (NAb). The same panel of FeLV tests was performed for
all cats, on the same blood samples collected at a single time point, as outlined below. Occasionally,
insufficient sample volume precluded all tests from being performed.
Whole blood samples were collected into two EDTA tubes from each cat and transported on ice to
the UoS within 6 hours of collection. One tube was centrifuged for 3 min at 12,000× g and harvested
plasma was aliquoted into two plain tubes using a sterile pipette and stored at −80 ◦C. At the end of
the sampling period, one aliquot of frozen plasma from each cat was transported on dry ice to the
University of Zurich for qRT-PCR testing and laboratory-based p27 ELISA testing, while the other
aliquot of frozen plasma was thawed and transported on ice to the University of Glasgow for NAb
testing. PoC testing with three FeLV kits (used concurrently) was performed with whole blood samples
at the UoS, within 24 h of blood collection using the second EDTA tube, and DNA extraction from
leukocytes was performed using sample collected in the same EDTA tube within 72 h of collection and
stored at −80 ◦C for batch qPCR testing at the UoS.
Results from these analyses enabled classification of cats as FeLV-uninfected or FeLV-infected,
using the following definitions (Table 1). FeLV-uninfected cats included FeLV-unexposed cats
(p27-negative, qPCR-negative, NAb-negative) and FeLV-abortive infections (p27-negative, qPCR-negative,
NAb-positive). FeLV-infected cats included cats with a ‘presumptively regressive infection’ (p27-negative,
qPCR-positive, NAb negative or positive) and cats with a ‘presumptively progressive infection’
(p27-positive, qPCR-positive, NAb negative or positive). FeLV-vaccinated cats uncommonly produce
NAb following vaccination without exposure [26–28], and instead, FeLV vaccination is thought to
‘prime’ the immune system and boost the NAb response following exposure [7]. Consequently,
FeLV-vaccinated/FeLV-uninfected cats that tested NAb-positive were considered FeLV-vaccinated cats that
had come into contact with the virus and were classified as ‘presumptively abortive infections’ (versus
FeLV-unvaccinated/FeLV-uninfected cats that tested NAb-positive and were considered as ‘definitively
abortive infections’). ‘Presumptively’ regressive and progressive infections were described because, in the
absence of repeated testing, a transient viraemia may have been present in some cats, resulting in some
regressive infections being incorrectly classified as progressive infections [1,2,29]. Detection of vRNA
by qRT-PCR testing was not included in the definition for progressive infections, as has been suggested
elsewhere, since residual plasma was not available from all FeLV-infected cats for testing [17,29].
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Table 1. Definitions used for defining each cat’s FeLV status in the current study, based on results from
the panel of FeLV tests performed.
FeLV Infection Status Category
Results from FeLV Tests Performed
PoC Testing (No.
of Positive Kits) qPCR Nab
1
FeLV-unexposed 0/3 − −
FeLV-uninfected
Definitively abortive
infection
(FeLV-unvaccinated cats)
0/3 − +
Presumptively abortive
infection
(FeLV-vaccinated cats)
0/3 − +
FeLV-infected
Presumptively
regressive infection 0/3 + −/+
Presumptively
progressive infection 1/3, 2/3 or 3/3 + −/+
+ = positive result, − = negative result. 1 There was insufficient sample volume from some cats for NAb testing.
2.2.1. FeLV PoC p27 Testing
SNAP Combo® (IDEXX Laboratories, Westbrook, ME, USA), Witness® (Zoetis Animal Health,
Lyon, France), and Anigen Rapid® (BioNote, Gyeonggi-do, Korea) FeLV test kits were used according
to the manufacturers’ instructions [14]. The specificity and sensitivity for the detection of progressive
FeLV infection have been estimated to be 94% and 100% for SNAP Combo®, respectively, and 98%
and 91% for Witness® and Anigen Rapid®, respectively [30]. Cats were considered p27-positive if
any of the three PoC kits tested returned a positive result (in combination with a positive qPCR result,
otherwise a false-positive p27 result was declared), and p27-negative if all three kits returned a negative
result [14].
2.2.2. FeLV qPCR Testing
DNA extraction from leukocytes in EDTA-anticoagulated whole blood and semi-quantitative
qPCR testing was performed to detect FeLV provirus as described previously, using a cycle threshold
(CT) cut-off of 40 [14,31]. DNA was extracted from 200 µL of blood using a kit (QIAamp DNA Mini Kit
(Qiagen, Valencia, CA, USA)), and 3 µL of DNA (approximately 100 ng) was added per 25 µL qPCR
reaction [14].
qPCR analysis for genomic mammalian DNA (feline 28S rDNA gene) was also performed using a
published protocol to assess the quality of the thawed DNA [14,32,33]. Samples with a CT value of less
than 37 were recorded as a positive result [14].
2.2.3. FeLV qRT-PCR Testing
A described real-time TaqMan qRT-PCR assay was used to detect FeLV RNA in plasma
(vRNA), with some modifications [31]. Briefly, total nucleic acid (TNA) was extracted from
100–200 µL of EDTA-anticoagulated plasma using the MagNA Pure LC Total Nucleic Acid Kit
(Roche Diagnostics, Mannheim, Germany) and an elution volume of 100 µL. In all the extractions,
negative controls consisting of phosphate buffered saline (PBS) were extracted in parallel to monitor
for cross-contamination. The 25 µL qRT-PCR reaction contained 5 µL TNA, 12.5 µL 2× RT-PCR
Buffer, 1 µL 25× RT-PCR Enzyme Mix (AgPath-IDTM One-Step RT-PCR Reagents, Thermo Fisher
Scientific), a final concentration of 900 nM of forward primer (FeLV_U3_exo_f), 300 nM of reverse
primer (FeLV_U3_exo_r), and 200 nM of fluorogenic probe (exoFeLV-U3-probe). Testing was performed
using an ABI PRISM 7500 Fast Sequence Detection System (Applied Biosystems, Foster City, CA,
USA). The temperature profile was 10 min at 45 ◦C, followed by 10 min at 95 ◦C, and then 40 cycles
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of 15 seconds at 95 ◦C and 45 s at 60 ◦C. Negative (PBS), positive (RNA standard template [31]) and
extraction controls were included in each run. Not all samples were available for qRT-PCR testing.
2.2.4. Laboratory-Based FeLV p27 ELISA Testing
The accuracy of laboratory-based FeLV p27 testing was compared to FeLV PoC p27 testing, with the
overall PoC result being taken as correct. If a cat tested p27-negative with the laboratory-based ELISA,
p27-positive with 1/3, 2/3, or 3/3 PoC test kits, and PCR-positive, it was declared truly p27-positive (and
false-negative with the laboratory-based ELISA). If a cat tested p27-positive with the laboratory-based
ELISA, p27-negative with 3/3 PoC test kits, and PCR-positive, it was declared p27-negative (and
false-positive with the laboratory-based ELISA). Residual plasma samples from qRT-PCR testing
were tested using a double-antibody sandwich ELISA using monoclonal antibodies to three epitopic
regions of p27, as described [34]. The results were calculated as the percentages of a defined positive
control (plasma from an experimentally FeLV-infected specific pathogen free cat) run with each test;
samples that tested >4% of the positive control were considered p27-positive [35]. Not all samples
were available for p27 antigen testing by laboratory-based ELISA.
2.2.5. FeLV NAb Testing
NAb were detected using the focus reduction test described [26]. Briefly, QN10 cells were
incubated overnight in 12 well plates (5 × 104 cells/mL) before the addition of 4 × 102 FFU/mL of
FeLV-A/Glasgow-1 that had been incubated for 2 hours with an equal volume of two-fold serial
dilutions of plasma samples (1/4, 1/8, 1/16, and 1/32) and the residual infectivity was measured. The
NAb titres were recorded as the reciprocals of the plasma dilutions that reduced the focus count of
FeLV by 75% compared with the virus control that had been incubated without plasma. A NAb titre
of 4 was considered weakly NAb-positive, while a titre of 32 was considered strongly NAb-positive.
Some samples had insufficient volume for NAb testing.
2.3. Statistical Analysis Including Mapping of Cases of FeLV Exposure and Infection
Numerical analyses were performed using the statistical software Genstat 16th Edition (GenStat
16th Edition for Windows, VSN International, Hemel Hempstead, United Kingdom) and R (The R
Foundation, Vienna, Austria). A Shapiro–Wilk test was used to assess data for normality. Normally
distributed data were analysed using restricted maximum likelihood (REML) modelling, while
non-normal data were analysed using Mann–Whitney U-tests. Since CT values were not normally
distributed, both median and geometric mean values are reported. Two-tailed Fisher’s exact tests
were applied to compare binomial outcomes, except when the expected frequency was ≥5 when
a Chi-squared test was used. Cohen’s Kappa Index Value (κ) was calculated to assess the level of
agreement between the laboratory-based p27 ELISA and p27 PoC testing, using the standard formula
(κ = 1 − (1 − Po)/(1 − Pe)), where Po was the observed agreement and Pe was the expected agreement
(0.5). Cases were mapped based on reported postcode of residence by joining these to a postcode
shapefile of Australia (ArcGIS version 10.1 [ESRI, Redlands, CA, USA]). Potential geographic ‘hot
spots’ of FeLV exposure (i.e., abortive infections) and FeLV infection (i.e., regressive and progressive
infections) in Group 1, based on postcode longitude and latitude centroid coordinates, were investigated
using the scan statistic SaTScan version 9.4.1 (Boston, MA, USA, www.satscan.org). A Bernoulli
model (case-control) was used, and both circular and elliptical scanning windows of up to 50% of
the population at risk were investigated to identify clusters based on likelihood statistics (999 Monte
Carlo simulations).
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3. Results
3.1. Description of Study Population (n = 529)
Cats in Group 1 (n = 440) were aged 2–20 years (median 7 years; interquartile range [IQR]
5–10 years), comprising 229 (52%) castrated males, 207 (47%) spayed females, and four (1%) entire
males. The majority were non-pedigree cats (371/440, 84%).
Cats in Group 2 (n = 38) were aged 1–14 years (median 4 years; IQR 3–10 years), comprising 15
(39%) castrated males and 23 (61%) spayed females. Most were non-pedigree cats (36/38, 95%).
Cats in Group 3 (n = 51) were aged 3 months to 5 years (median 1 year; IQR 0.4–2 years),
comprising 23 (45%) castrated males, 27 (53%) spayed females, and one entire female (2%). Most were
non-pedigree cats (49/51, 96%).
The median ages of Groups 1, 2, and 3 were significantly different (7 years, 4 years, and 1 year;
p < 0.01; REML testing). The proportion of males and females in each group was similar (p = 0.11;
REML testing).
3.2. Identification of FeLV-Infected Cats
In total, 52 FeLV-infected cats, including 31 presumptively regressive infections (Group 1—9/440,
2%; Group 2—7/38, 18%; Group 3—15/51, 29%) and 21 presumptively progressive infections (Group
1—2/440, 0.5%; Group 2—7/38, 18%; Group 3—12/51, 24%), were identified (Table 2).
Considering results from all three groups together, the median age of presumptively
regressively-infected cats (range 2–16 years, median 10 years) was greater than the median age
of presumptively progressively-infected cats (range 0.4–11 years, median 5 years), although the
difference did not reach statistical significance (p = 0.064; Mann–Whitney U-test), and the ages of only
3/27 FeLV-infected cats in Group 3 were known. There was no sex predilection for either presumptively
regressive or progressive infections (p = 0.71 and p = 0.38, respectively; Fisher’s exact tests), nor any
breed predilection (i.e., non-pedigree versus pedigree cats; p = 1.00 for regressive infections, p = 0.10
for progressive infections; Fisher’s exact tests).
In Group 1, three presumptively regressively-infected cats and one presumptively
progressively-infected cat had been vaccinated against FeLV, although these four cats had not been
FeLV tested prior to initial vaccination.
3.3. Detection of FeLV Provirus by qPCR
EDTA-anticoagulated samples were available from all 529 cats for qPCR testing. Presumptively
progressively-infected cats demonstrated significantly lower median qPCR CT values (median 21,
geometric mean 23, range 17–37, IQR 18–29) compared to presumptively regressively-infected cats
(median 35, geometric mean 35, range 28–40, IQR 33–37; p < 0.001; Mann–Whitney U-test). There was
some overlap of qPCR CT values between presumptively regressively and progressively-infected cats
(Figure 2) and five presumptively progressively-infected cats (one in Group 1 and four in Group 3) had
low proviral loads (CT values > 30).
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Figure 2. Scatter plot of CT values (y-axis) from FeLV qPCR testing of EDTA-anticoagulated whole
blood samples for the three groups of cats by type of FeLV infection (x-axis). Samples with a CT value
of less than 40 were recorded as a positive result. Presumptively progressively FeLV-infected cats
(n = 21) recorded a significantly lower median qPCR CT value (i.e., higher proviral load) compared to
presumptively regressively FeLV-infected cats (n = 31) (p < 0.001).
The median CT value from feline 28S rDNA qPCR testing was 29 (geometric mean 29, range 27–36,
IQR 28–30). All samples, with one exception, returned a CT value below 35, confirming the adequate
quality of the thawed DNA. The one exception (CT value of 36.4) was from a cat in Group 1 that tested
p27-negative and qPCR-negative for FeLV proviral DNA.
3.4. Detection of FeLV RNA by qRT-PCR
Insufficient plasma was available from three presumptively regressively-infected and three
presumptively progressively-infected cats to perform qRT-PCR testing for FeLV RNA (Table 3).
Presumptively progressively-infected cats were more likely to test vRNA-positive than presumptively
regressively-infected cats (16/18, 89% versus 6/28, 21%; p < 0.001; Chi-squared test; Figure 3).
When presumptively progressively-infected cats tested vRNA-positive, they recorded significantly
lower median qRT-PCR CT values (median 18, geometric mean 19, range 15–34, IQR 17–19) than
presumptively regressively-infected cats (median 35, geometric mean 35, range 32–39, IQR 34–38;
p < 0.001; Mann–Whitney U-test; Figure 3). The two presumptively progressively-infected cats testing
vRNA-negative tested p27-positive using only one PoC kit (SNAP Combo®; Table 4). Presumptively
regressively-infected cats that tested vRNA-positive had significantly lower median qPCR CT values (i.e.,
higher levels of proviral DNA) than presumptively regressively-infected cats that tested vRNA-negative
(p = 0.008; Mann–Whitney U-test). The same was true for presumptively progressively-infected cats
(p < 0.001; Mann–Whitney U-test).
None of the 39 samples available from FeLV-uninfected cats tested vRNA-positive.
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Figure 3. Scatter plot of CT values (y-axis) from FeLV qRT-PCR testing of EDTA-anticoagulated
plasma samples for the three groups of cats by type of FeLV infection (x-axis). Samples with a CT
value of less than 40 were recorded as a positive result. Presumptively progressively FeLV-infected
cats (n = 18) were significantly more likely to test vRNA-positive than presumptively regressively
FeLV-infected cats (n = 28; p < 0.001), and when presumptively progressively-infected cats tested
vRNA-positive they recorded a significantly lower median qRT-PCR CT value than presumptively
regressively-infected cats (p < 0.001). Samples from FeLV-infected cats that tested vRNA-negative are
not shown (22 presumptively regressively-infected cats and 2 presumptively progressively-infected
cats; refer to Table 4 for more details).
3.5. Laboratory-Based FeLV p27 ELISA
Insufficient plasma was available from seven presumptively regressively-infected and four
presumptively progressively-infected cats for testing with the laboratory-based FeLV p27 ELISA. Of
the remaining 41 FeLV-infected cats, 0/24 presumptively regressively-infected and 15/17 presumptively
progressively-infected cats tested p27-positive. None of the 38 samples available from FeLV-uninfected
cats tested p27-positive. There was 98.7% test agreement (78/79) between testing with the
laboratory-based ELISA and PoC testing with SNAP Combo® (κ = 0.962, 95% confidence interval [CI]
0.887-1), 98.7% test agreement (78/79) between ELISA and Witness® (κ = 0.960, 95% CI 0.882-1), and
97.5% test agreement (77/79) between ELISA and Anigen Rapid® (κ = 0.918, 95% CI 0.806-1).
3.6. Dete tion of FeLV NAb
Insufficient plasma was available for NAb testing from 12 FeLV-uninfected cats (10 FeLV-vaccinated
and 2 FeLV-unvaccinated) in Group 1, nine FeLV-uninfected rescue cats, two presumptively
regressively-infected cats, and six presumptively progressively-infected cats (Table 3).
Considering FeLV-uninfected cats in Group 1, there were 370 NAb-negative results (i.e.,
FeLV-unexposed cats; 370/440, 84%), and 47 NAb-positive results (47/440, 11%; Table 3 and Figure 4).
Of the 370 FeLV-unexposed cats, 84 cats were FeLV-vaccinated (including 42 vaccinated on-time and 42
overdue for vaccination) and 286 cats were FeLV-unvaccinated. Of the 47 NAb-positive cats, all were
FeLV-vaccinated (17 with Fel-O-Vax Lv-K®, 30 with Fel-O-Vax F5®) and were therefore considered
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presumptively abortive infections (i.e., vaccinated and exposed). Most of these cats (37/47, 79%) had
been vaccinated within 12 months of testing, with the remainder overdue for vaccination by between 3
days and 5.6 years. There was a strong association between FeLV vaccination and the presence of NAb
(p < 0.001; Chi-squared test).
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Figure 4. Summary of anti-FeLV NAb results in Group 1 (n = 428), recorded as the reciprocals of
the plasma dilutions that reduced the focus count of FeLV by 75% compared with the virus control
that ha been incubated without plasma. A NAb titre of 4 was considered weakly NAb-positive,
whil a titre of 32 was c nsidered strongly NAb-positive. Sufficient sample was availabl from 131
FeLV-vaccin ted/FeLV-uninfected cats, 286 FeLV-unvaccinated/FeLV-uninfected cats, 9 presumptively
regressively FeLV-infected cats, and 2 presumpti ely progressively FeLV-infected cats fo NAb testing.
Co sidering FeLV-uninfected cats from the two rescue facilities together, 31/89 (35%) tested
NAb-negative and were classified as FeLV-unexposed (Group 2—15/38, 39%; Group 3—16/51, 31%).
Four FeLV-uni fected cats in Group 2 (4/38, 11%) and four in Group 3 (4/51, 8%) tested NAb-positive
and were classified as definitively abortive infections.
Considering FeLV-infected cats from all three groups together, presumptively regressively-infected
cats were more likely than presumptively progressively-infected cats to test NAb-positive (27/29,
93% versus 3/15, 20%; p = 0.000002; Fisher’s exact test). Three of the 27 NAb-positive samples from
presumptively regressively-infected cats were from FeLV-vaccinated individuals (two on-time, one
overdue; Table 4). The two presumptively regressively-infected cats that tested as NAb-negative were
FeLV-unvaccinated. The one presumptively progressive infection that had been vaccinated on-time
against FeLV was NAb-negative, while the three presumptively progressively-infected cats that tested
NAb-positive were FeLV-unvaccinated (Table 4).
3.7. FIV Infection Status and FeLV/FIV Co-Infections
Thirty-nine cats were identified as FIV-infected based on FIV PoC testing [25], comprising 32 cats
from Group 1 (32/440, 7%), three cats from Group 2 (3/38, 8%), and four cats from Group 3 (4/51, 8%).
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FIV-infected cats were aged 3–16 years (median 7 years; IQR 5–9 years), comprising 27 (69%) castrated
males, 11 (28%) spayed females, and one (3%) entire male. Most FIV-infected cats were non-pedigree
cats (35/39, 90%). Male cats were significantly more likely to be FIV-infected than female cats (p = 0.008;
Fisher’s exact test; odds ratio 2.6, 95% CI 1.3–5.3). The age of only one FIV-infected cat in Group 3
was known.
Five cats infected with FeLV, two presumptively regressively-infected and three presumptively
progressively-infected, were co-infected with FIV. FeLV/FIV co-infected cats were as likely to be
presumptively progressively-infected as presumptively regressively-infected, compared to cats infected
with only FeLV (3 and 2 versus 18 and 29, respectively; p = 0.64; Fisher’s exact test). Cats were more
likely to be infected with just one retrovirus (either FeLV or FIV) than to be co-infected (p < 0.001;
Chi-squared test). Considering only FeLV-uninfected cats, FIV-infected cats were as likely to test
NAb-positive as FIV-uninfected cats (2/31 versus 43/386; p = 0.56; Fisher’s exact test).
3.8. Mapping of Cases of FeLV Exposure and Infection (Group 1 Only)
Using circular and elliptical scanning windows, a cluster of abortive infections (i.e., FeLV-exposed
cats) was consistently identified in western Sydney, New South Wales (NSW; Figure 5). Based on an
elliptical scanning window of up to 10% of the population at risk, this cluster included postcodes
2170, 2173, and 2177, encompassing an area between Liverpool and Campbelltown (latitude 33.934◦ S,
longitude 150.912◦ E). Within this cluster there were 15 abortive infections out of a sample population
of 40 cats. Based on this scanning window, 4.5 cases were expected, an observed-to-expected ratio of
3.34 (p = 0.0084).
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Figure 5. Scanning windows were used to investigate the possibility of clusters of FeLV
exposure/infection in Group 1. Based on a scanning window of up to 10% of the population at
risk, a cluster of abortive infections (i.e., FeLV-exposed cats) was identified in western Sydney, New
South Wales (postcodes 2170, 2173, and 2177; grey shading).
Also using circular and elliptical scanning windows, two potential geographical ‘hot spots’ of
FeLV infection were identified in Group 1, one in western Sydney, NSW (postcode 2145; 4 cases
reported, 1.6 cases expected), and one in Geelong, Victoria (postcodes 3218, 3219 and 3220; 3 cases
reported, 0.58 cases expected). However, neither were statistically significant (p ≥ 0.60).
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Table 2. Summary of results from the current study.
Group Description FeLV-Uninfected 1
FeLV-Infected
Presumptively Regressive
Infections 2
Presumptively
Progressive Infections 3
Ratio Regressive:Progressive
Infections
Group 1 (n = 440)
Healthy, client-owned cats recruited
predominantly from eastern Australia as
part of a study into the effectiveness of a
commercially available FIV vaccine
429/440 (98%), including
47/440 (11%) presumptively
abortive infections
9/440 (2%), including 0/8 with
detectable circulating vRNA 2/440 (0.5%) 4.5
Group 2 (n = 38)
Mixture of healthy and sick cats being
group-housed at a rescue facility with
recent cases of FeLV infection
24/38 (63%), including 4/38
(11%) abortive infections
7/38 (18%), including 1/6
(17%) with detectable
circulating vRNA
7/38 (18%) 1.0
Group 3 (n = 51)
Mixture of healthy and sick cats being
group-housed at a rescue facility with
recent cases of FeLV infection
24/51 (47%), including 4/51
(8%) abortive infections
15/51 (29%) including 5/14
(36%) with detectable
circulating vRNA
12/51 (24%) 1.25
1 FeLV-uninfected cats were defined as those that were p27-negative with three PoC test kits and proviral qPCR-negative. 2 FeLV-infected cats with presumptively regressive infections
were defined as those that were p27-negative with three PoC test kits and proviral qPCR-positive. 3 FeLV-infected cats with presumptively progressive infections were defined as those that
were p27-positive with at least one of three PoC test kits and proviral qPCR-positive.
Table 3. Summary of results from NAb testing, laboratory-based p27 testing, and qRT-PCR testing. Not all samples were available for testing. NP = not performed.
Group Negative NAb
Result (<4)
Positive NAb Result
Positive Laboratory-Based
p27 ELISA
Positive qRT-PCR
4 (weak) 8 16 ≥32 (strong) Total NAbPositive
1 FeLV-uninfected (n = 429) 370 16 15 10 6 47/417 1 NP NP
1 Presumptively regressiveinfections (n = 9) 2 0 1 1 5 7/9 0/6 0/8
1 Presumptively progressiveinfections (n = 2) 2 0 0 0 0 0/2 1/1 1/1
2 FeLV-uninfected (n = 24) 15 0 0 2 2 4/19 0/18 0/19
2 Presumptively regressiveinfections (n = 7) 0 0 1 0 5 6/6 0/5 1/6
2 Presumptively progressiveinfections (n = 7) 1 0 0 0 0 0/1 6/6 6/6
3 FeLV-uninfected (n = 24) 16 0 1 1 2 4/20 0/20 0/20
3 Presumptively regressiveinfections (n = 15) 0 0 0 1 13 14/14 0/13 5/14
3 Presumptively progressiveinfections (n = 12) 9 0 0 0 3 3/12 8/10 9/11
1 10/12 samples not available for NAb testing were from FeLV-vaccinated cats.
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Table 4. Summary of individual results for presumptively regressively-infected (n = 31) and presumptively progressively-infected cats (n = 21), arranged in descending
order of CT value for qPCR testing (i.e., from lower levels of FeLV provirus to higher levels of FeLV provirus). Occasionally, there was insufficient sample volume for
laboratory-based p27 ELISA, qRT-PCR, and NAb testing. + = positive result, − = negative result, NP = not performed.
Cat ID Presumptive Category
of Infection
FeLV Vaccination
Status
Test Performed
PoC Testing (No.
of Positive Kits)
Laboratory-Based
p27 ELISA qPCR CT qRT-PCR CT NAb Assay
Group 1 - #41 Regressive Unvaccinated 0/3 - 39.8 - -
Group 1 - #386 Regressive Unvaccinated 0/3 NP 39.2 NP + (≥ 1/32)
Group 1 - #141 Regressive On-time 0/3 - 39.1 - + (1/8)
Group 1 - #251 Regressive Unvaccinated 0/3 NP 37.6 - + (≥ 1/32)
Group 2 - #15 Regressive Unvaccinated 0/3 - 37.5 - + (1/8)
Group 3 - #19 Regressive Unvaccinated 0/3 - 37.3 - + (≥ 1/32)
Group 3 - #5 Regressive Unvaccinated 0/3 - 37.2 - + (≥ 1/32)
Group 1 - #71 Regressive On-time 0/3 NP 37.1 - + (≥ 1/32)
Group 3 - #13 Regressive Unvaccinated 0/3 - 36.9 - + (1/16)
Group 2 - #3 Regressive Unvaccinated 0/3 - 36.8 - + (≥ 1/32)
Group 3 - #7 Regressive Unvaccinated 0/3 NP 36.6 - + (≥ 1/32)
Group 1 - #48 Regressive Overdue (last given11.2 years prior) 0/3 - 36.4 - + (1/16)
Group 3 - #38 Regressive Unvaccinated 0/3 - 36.2 39.1 + (≥ 1/32)
Group 3 - #6 Regressive Unvaccinated 0/3 - 36.2 - + (≥ 1/32)
Group 3 - #36 Regressive Unvaccinated 0/3 - 35.4 - + (≥ 1/32)
Group 3 - #18 Regressive Unvaccinated 0/3 - 35.3 - + (≥ 1/32)
Group 3 - #34 Regressive Unvaccinated 0/3 - 35.2 - + (≥ 1/32)
Group 3 - #17 Regressive Unvaccinated 0/3 NP 35.1 NP NP
Group 2 - #22 Regressive Unvaccinated 0/3 - 35.0 - + (≥ 1/32)
Group 1 - #287 Regressive Unvaccinated 0/3 - 34.9 - + (≥ 1/32)
Group 1 - #252 Regressive Unvaccinated 0/3 - 34.5 - + (≥ 1/32)
Group 2 - #38 Regressive Unvaccinated 0/3 NP 34.4 - + (≥ 1/32)
Group 1 - #258 Regressive Unvaccinated 0/3 - 34.1 - -
Group 3 - #27 Regressive Unvaccinated 0/3 - 33.2 - + (≥ 1/32)
Group 3 - #15 Regressive Unvaccinated 0/3 - 33.1 38.4 + (≥ 1/32)
Group 2 - #13 Regressive Unvaccinated 0/3 - 32.9 31.8 + (≥ 1/32)
Group 3 - #33 Regressive Unvaccinated 0/3 - 31.2 33.7 + (≥ 1/32)
Group 3 - #52 Regressive Unvaccinated 0/3 - 31.2 35.9 + (≥ 1/32)
Group 3 - #29 Regressive Unvaccinated 0/3 - 31.2 33.7 + (≥ 1/32)
Group 2 - #36 Regressive Unvaccinated 0/3 NP 29.4 NP NP
Group 2 - #4 Regressive Unvaccinated 0/3 - 28.0 - + (≥ 1/32)
TOTAL POSITIVE
(presumptively regressive) 3/31 vaccinated 31 × 0/3 0/24 31/31 6/28 27/29
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Table 4. Cont.
Cat ID Presumptive Category
of Infection
FeLV Vaccination
Status
Test Performed
PoC Testing (No.
of Positive Kits)
Laboratory-Based
p27 ELISA qPCR CT qRT-PCR CT NAb Assay
Group 3 - #3 Progressive Unvaccinated 1/3 1 + (43.5%) 37.1 - + (≥ 1/32)
Group 3 - #12 Progressive Unvaccinated 1/3 1 - 36.4 - + (≥ 1/32)
Group 1 - #330 Progressive Unvaccinated 1/3 1 NP 35.3 NP -
Group 3 - #40 Progressive Unvaccinated 3/3 + (13.4%) 31.3 31.1 -
Group 3 - #9 Progressive Unvaccinated 3/3 + (6.4%) 31.1 34.1 -
Group 3 - #50 Progressive Unvaccinated 3/3 - (1.5%) 28.2 27.4 + (≥ 1/32)
Group 2 - #21 Progressive Unvaccinated 3/3 + (24.9%) 22.7 18.9 NP
Group 3 - #51 Progressive Unvaccinated 3/3 + (61.2%) 22.5 18.6 -
Group 3 - #10 Progressive Unvaccinated 3/3 + (80.0%) 21.5 18.5 -
Group 2 - #30 Progressive Unvaccinated 3/3 + (35.1%) 21.4 17.7 NP
Group 3 - #16 Progressive Unvaccinated 3/3 NP 21.3 NP -
Group 2 - #31 Progressive Unvaccinated 3/3 + (36.6%) 21.3 17.0 NP
Group 2 - #5 Progressive Unvaccinated 3/3 + (59.2%) 19.2 17.7 NP
Group 2 - #20 Progressive Unvaccinated 3/3 + (27.2%) 19.2 17.1 NP
Group 3 - #26 Progressive Unvaccinated 3/3 NP 18.4 16.5 -
Group 3 - #31 Progressive Unvaccinated 3/3 + (105.2%) 18.3 15.2 -
Group 2 - #7 Progressive Unvaccinated 3/3 + (26.7%) 18.2 18.5 NP
Group 2 - #14 Progressive Unvaccinated 3/3 NP 18.0 NP -
Group 3 - #39 Progressive Unvaccinated 3/3 + (49.3%) 17.8 15.6 -
Group 3 - #42 Progressive Unvaccinated 3/3 + (65.2%) 17.6 15.3 -
Group 1 - #62 Progressive On-time 3/3 + (55.9%) 16.8 18.7 -
TOTAL POSITIVE
(presumptively progressive) 1/21 vaccinated 3 × 1/3, 18 × 3/3 15/17 21/21 16/18 3/15
1 only tested p27-positive with SNAP Combo®.
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Table 5. Outcomes of FeLV-infected cats in Groups 1 and 2 at the time of writing. All were non-pedigree cats except for #141 in Group 1 that was a Tonkinese, #258 in
Group 1 that was a Chinchilla and #4 in Group 2 that was a Birman. Due to the field nature of the study, it is not known how long cats had been infected for at the time
of diagnosis. When known, the time elapsed between diagnosis and final outcome is noted. The approximate time between diagnosis and manuscript writing was 4–6
years. MN = male neutered, FS = female spayed, CKD = chronic kidney disease.
Cat ID Age at Time ofDiagnosis (Years) Sex Outcome
PRESUMPTIVELY REGRESSIVE INFECTIONS
Group 1 - #41 15 MN Found dead 25 months after diagnosis, suspected due to progression of CKD
Group 1 - #48 12 MN Lost to follow up
Group 1 - #71 6 FS Alive and doing well at the time of writing
Group 1 - #141 15.8 MN Euthanased 15 months after diagnosis due to progression of CKD
Group 1 - #251 2.3 MN Lost to follow up
Group 1 - #252 4.9 MN Lost to follow up
Group 1 - #258 10.2 FS Lost to follow up
Group 1 - #287 7.6 MN Lost to follow up
Group 1 - #386 11.4 MN Lost to follow up
Group 2 - #3 10 FS Alive and doing well at the time of writing. Stable diabetic (in remission at the time of writing)
Group 2 - #4 14 FS Euthanased due to suspected cardiomyopathy
Group 2 - #13 10 MN Euthanased due to geriatric-related disease
Group 2 - #15 5 FS Alive and doing well at the time of writing
Group 2 - #22 4 MN Found dead, suspected due to brown snake bite
Group 2 - #36 13 FS Euthanased due to progression of CKD
Group 2 - #38 3 FS Lost to follow up (ran away)
PRESUMPTIVELY PROGRESSIVE INFECTIONS
Group 1 - #62 3.4 MN Euthanased 8 months after diagnosis since not doing well (inappetent and constipated)
Group 1 - #330 6.4 FS Alive and doing well at the time of writing
Group 2 - #5 11 FS Euthanased 24 months after diagnosis due to mass in abdomen, post-mortem not performed
Group 2 - #7 11 FS Euthanased due to progression of CKD
Group 2 - #14 4 MN Euthanased due to multiple diffuse skin masses, one month after FeLV diagnosis. Feline sarcoma virus (FeSV)infection was diagnosed post-mortem (histopathology and gp70 staining of masses)
Group 2 - #20 8 MN Euthanased 38 months after diagnosis due to nasal cavity tumour
Group 2 - #21 9 MN Euthanased 13 months after diagnosis due to breathing difficulties, cardiac disease suspected due to severe heartmurmur, post-mortem not performed, co-infected with FIV
Group 2 - #30 2 MN Euthanased 22 months after diagnosis due to breathing difficulties, post-mortem revealed mediastinal lymphoma
Group 2 - #31 2 MN Euthanased 6 months after diagnosis, severe non-regenerative anaemia and icterus, post-mortem revealedhepatomegaly, splenomegaly, pericardial effusion and pleural effusion
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3.9. Follow-up of Rescue Cats and FeLV-Infected Cats (Groups 1 and 2 Only)
All FeLV-uninfected cats in Groups 2 and 3 were vaccinated against FeLV with Fel-O-Vax
F5® or Leucogen® (two primary vaccinations given one month apart, as per the manufacturers’
instructions). Husbandry advice and assistance with FeLV/FIV testing of new animals were also
provided to both rescue facilities to reduce the incidence and impact of retroviral disease in the
cat populations. Cats in Group 2 were closely followed clinically and sampled regularly; repeated
testing of presumptively progressively-infected cats (tested up to six times over two years) confirmed
all seven remained p27-positive and were likely progressively-infected according to the European
Pharmacopoeia (p27-positive for three consecutive weeks or on five occasions between weeks 3 and 15
post-exposure [36]). A summary of outcomes for presumptively regressively and progressively-infected
cats in Groups 1 and 2 is provided in Table 5; at least 14 were deceased at the time of writing, including
6/16 regressively-infected cats and 8/9 progressively-infected cats, and 7/16 regressively-infected cats
were lost to follow-up. Cats in Group 3 were lost to follow-up.
4. Discussion
This study reports a comprehensive analysis of the prevalence of FeLV exposure and FeLV
infection of cats in Australia. Results from Group 1 demonstrated that, despite the relatively low
overall prevalence of FeLV infection in the general pet population, a finite risk of exposure to FeLV
is present, with 47 FeLV-uninfected cats (11%) in the current study testing positive for NAb to FeLV.
Presumptively regressive infections were 4.5 times more common than presumptively progressive
infections in this cohort, higher than other ratios reported in the literature (0.7–1.5) [18,33,35,37,38],
including the only other Australian study to use p27 detection and PCR testing for proviral DNA [37].
The differences in ratios may in part reflect differences in recruitment criteria between the various
studies, for example, the large proportion of healthy cats recruited in our Group 1 compared to other
surveys that included a variable proportion of ‘sick cats’. In addition, the cohort for the other Australian
study was recruited from a single city (Sydney), whereas the current study recruited cats from a wider
area [37]. The prevalence of progressive infections in the healthy cat population in Australia appears
to have remained stable over the past 20 years at 0–2% [5,39,40]. Samples from Western Australia were
not available for testing as part of Group 1, which was unfortunate as its capital, Perth, is thought to
have the highest FeLV prevalence of any Australian state or territory [5].
Results from two rescue facilities experiencing symptomatic FeLV outbreaks (Groups 2 and 3)
demonstrated that clusters of cases occur in Australia in exposed, immunologically naïve cats, with
a mixture of abortive, regressive, and progressive infections identified. The ratio of presumptively
regressive:progressive infections in these cohorts was 1–1.25, suggesting that progressive infections
are more likely in multi-cat situations compared to the general pet cat population [38], probably as a
consequence of a combination of factors including higher virus exposure, higher infective doses, and
higher stress levels resulting from the proximity to numerous other cats [41]. With time, and removal of
progressively-infected cats due to death, illness, and/or euthanasia, the regressive to progressive ratio
in Groups 2 and 3 may have increased. The lower median ages of cats in Groups 2 and 3 compared to
Group 1 also likely contributed to the higher rates of progressive infections observed, as age-related
immunity to FeLV develops in older cats [42]. Despite the large number of viraemic FeLV-infected
cats at both rescue facilities, 39% (15/38) and 31% (16/51) of cats, respectively, were FeLV-unexposed
(i.e., FeLV-uninfected and NAb-negative). This perhaps reflects the solitary nature of many cats even
when group-housed [43], although abortive infections with primarily a cell-mediated rather than a
humoral immune response (resulting in a NAb-negative result) are also a possibility (as evidenced
by the two presumptively regressively-infected cats in Group 1 that tested NAb-negative) [7,18]. It
is also possible that cats in Groups 2 and 3 were tested relatively early during outbreaks of FeLV
infection at the two facilities, and that with repeated testing at later time points more cats might have
demonstrated exposure to FeLV. Moreover, it is possible that a minimal humoral immune response
after FeLV exposure could have been detectable in some of these cats using a recently described
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alternative approach to detect antibodies directed against the FeLV transmembrane antigen p15E [44].
In response to these outbreaks, we recommend that all young cats in Australia in contact with cats of
unknown retroviral status should have their FeLV status determined by PoC testing and, if negative,
be vaccinated against FeLV to protect them against the development of progressive infection [1,2].
Given that no benefit has been demonstrated for vaccinating cats with regressive infections against
FeLV, and considering the risk of feline injection site sarcomas associated with FeLV vaccination [45],
it is ideal to perform both FeLV PoC and PCR testing prior to vaccination. Currently, it is estimated
only 2% of Australian client-owned cats are vaccinated against FeLV (Phillip McDonagh per comms,
Technical Service Manager, Boehringer Ingelheim Animal Health, Australia). In addition, shelters and
boarding facilities that allow contact between cats should perform FeLV testing of all incoming cats
during a six-week quarantine period (followed by FeLV vaccination of FeLV-uninfected cats prior to
co-mingling), with segregated housing for all FeLV-infected cats [8].
Presumptively regressively-infected cats were more likely to test NAb-positive than presumptively
progressively-infected cats, highlighting the role an individual cat’s humoral immune response plays
in determining the outcome of FeLV exposure. Despite vaccination against FeLV, and irrespective
of which type of FeLV vaccine is administered, regressive infections still occur in some vaccinated
cats following natural or experimental challenge with FeLV [17,27,46–49]. In the current study, it
was impossible to determine whether the three presumptively regressively-infected cats that had
been vaccinated against FeLV had been infected prior to initial vaccination, since no pre-vaccination
FeLV testing had been performed. The impact of regressive FeLV infections on the health of cats is
largely unknown, as few studies have monitored cohorts of regressively-infected cats longitudinally
under field conditions to determine long-term outcomes. Some authors have suggested that regressive
FeLV-infected cats have a similar life-expectancy to cats unexposed to FeLV and that FeLV-associated
disease is unlikely to develop [2,7]. Conversely, reactivation of regressive FeLV infection constrained
in the bone marrow has been demonstrated experimentally, with and without the administration of
corticosteroids [17,20,50], and care is suggested when treating regressively FeLV-infected cats with
immunosuppressive medications (e.g., chemotherapy, chlorambucil, ciclosporin) [16,47]. Further
investigations on the impact of regressive FeLV infections on feline health under field conditions is
warranted. Identification of regressively-infected cats (such as the 31 cats in the current study) and
age-matched control cats will greatly facilitate longitudinal case-control studies.
Six presumptively regressively-infected cats (6/28, 21%) tested vRNA-positive, consistent with
previous observations that some regressively-infected cats are transcriptionally active (i.e., producing
vRNA), despite testing p27-negative and virus isolation negative [17,28]. Based on the ability of
regressively-infected cats (as well as progressively-infected cats) to transmit FeLV to other cats via
blood transfusion [51,52], this detection of vRNA indicates that there is a risk of FeLV transmission
from regressively-infected cats to naïve cats in the field via cat bite injuries and the possible transfer
of minute amounts of blood, particularly if the aggressor cat has significant periodontal disease. It
has also been suggested that transcriptionally active, regressively-infected cats are at greater risk for
reactivation of active FeLV infection than regressively-infected cats that test vRNA-negative [29]. It is
possible that repeated qRT-PCR testing may have shown that more regressively FeLV-infected cats
in the study were transcriptionally active, since repeated qRT-PCR testing is sometimes necessary to
diagnose such cases, reflecting fluctuations in vRNA levels in blood [17].
It could be speculated that the 47 FeLV-uninfected cats in Group 1 that tested NAb-positive and
were classified as abortive infections had never been exposed to FeLV, and only tested NAb-positive
in response to FeLV vaccination. However, we considered this scenario unlikely, based on results
from other studies. Firstly, a laboratory-based study of cats vaccinated with Fel-O-Vax Lv-K IV®
(distributed as Fel-O-Vax F5® in Australia), and monitored for production of NAb using the same NAb
assay as used in the current study, reported that 0/10 cats produced NAb prior to FeLV challenge [27].
Another laboratory-based study of cats vaccinated with Fel-O-Vax Lv-K®, and using a NAb assay
based on infection of AH9327 cells with vaccine-homologous virus (FeLV-A/61E), found 0/8 cats were
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NAb-positive prior to FeLV challenge [28]. In view of these results, we felt it appropriate to classify
these 47 FeLV-vaccinated cats (47/440; 11%) as presumptively abortive infections, especially considering
that two cats tested strongly NAb-positive and neither had been vaccinated for over six years. The
possibility of a cluster of FeLV exposure in western and southwestern Sydney further increased our
suspicion that this result represented a true estimate of the prevalence of abortive infections in Group
1. Further work, however, to investigate whether FeLV-vaccinated cats in the field can produce NAb
without natural exposure, would be worthwhile. The frequency of abortive infections in the field
is not well documented, with a study from Southern Germany identifying such infections using an
anti-p45 antibody ELISA (p45 being the non-glycosylated form of gp70, the FeLV surface envelope
glycoprotein) at a prevalence of 4% (22/495), in a population with 1% regressive infections (6/495) and
2% progressive infections (9/495) [18]. Abortive infections have been reported to occur in 20–30% of
cats challenged with FeLV under laboratory conditions, although this rate varies depending on the age
of exposed cats, route of infection and challenge dose [2,16]. It is even possible that the rate of abortive
infections in the current study was underestimated, since the NAb assay might not have detected
abortive infections in cats with predominantly cell-mediated immune responses.
A limitation of the current study was that cats were only available for testing at a single time
point (with the exception of FeLV-infected cats in Group 2), so that we classified cats tentatively as
‘presumptively regressive and progressive infections’ according to their p27, qPCR, and NAb results,
irrespective of their qRT-PCR result. In the absence of repeated testing, this may have meant that
some cats were misclassified. For example, one cat in Group 3 (#12) that tested p27-positive with
only 1/3 PoC test kits (SNAP Combo®), was p27-negative with the laboratory-based ELISA, had a
qPCR CT value of 36.4, tested vRNA-negative, and was strongly NAb-positive, was categorised as
a presumptively progressive infection (Table 4). The high qPCR CT value (low proviral load) of this
cat, in combination with an absence of vRNA, 3/4 p27-negative test results, and the presence of NAb,
were otherwise suggestive of a regressive infection with the absence of significant antigenemia. This
cat demonstrated the difficulties with discordant test result interpretation and of categorising cats
into the different FeLV infection outcomes, particularly when data is only available from a single time
point. The potential for errors with sample handling and labelling or laboratory contamination leading
to discordant and unexpected results is unlikely, but cannot be absolutely excluded. Regardless of
the classification system employed, p27-positive cats had mostly low qPCR CT values (15/21 less
than 25), while p27-negative cats had mostly high qPCR CT values (29/31 higher than 30) [6,33]. As
anticipated, presumptively progressively-infected cats were found to be more likely vRNA-positive
than presumptively regressively-infected cats [29]. Another cat in Group 3 (#50) categorised as a
presumptively progressive infection might also have had an early regressive infection, since it tested
p27-negative with the laboratory-based ELISA and was strongly NAb-positive, demonstrating an
effective immune response that is usually found only in cats with regressive infections [7,27,28]. The
third presumptively progressive infection that tested strongly NAb-positive in Group 3 (#3) displayed
discordant results, having a strongly p27-positive result with the laboratory-based ELISA (43.5%), but
was only p27-positive with 1/3 PoC test kits (SNAP Combo®), had a very low proviral load (qPCR CT
value of 37.1), and was vRNA-negative. A cat with such a high p27 antigen result would typically
display a higher proviral load and test vRNA-positive. Additional plasma testing at the University of
Zurich (results not shown) confirmed that this cat tested qRT-PCR-negative using three additional
sets of primers (including U3, env, and gag [35]). While prolonged storage and repeated freeze–thaw
cycles may have contributed to the negative vRNA result and also, to some extent, the low provirus
load, an alternative explanation could be the presence of a focal infection in this cat, with sequestered
virus replication in the absence of virus replication in the peripheral blood. Focal FeLV infections were
first described in the pre-PCR era, when about 10% of blood samples that tested positive with a p27
laboratory-based ELISA (detection of soluble antigen) were negative by virus isolation [53]. Testing
of some of these ’discordant’ samples at a later date with a nested PCR found a proportion of these
samples were PCR-positive (13/39, 33%) [54]. We would expect that cats with a focal infection would
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also test vRNA-negative. To the best of our knowledge, cat #3 in Group 3 is the first suspected case of a
focal infection that has appeared in the literature in over 20 years. It would be useful to follow this cat
over time to observe whether it succumbs to FeLV-related disease, and whether PCR testing of different
tissue types at post-mortem could identify the location/s of the suspected focal infection. These three
cats in Group 3 (#12, #50, and #3), and two additional cats in Group 3 with low proviral loads (qPCR
CT >30) but positive p27 test results (#9 and #40), all originated from a rescue facility with known
ongoing natural FeLV exposure; only one cat in the case-control study (Group 1, cat #330), showed a
similar pattern with varying p27 results (positive with 1/3 PoC test kits) and a low proviral load (qPCR
CT value of 35.3). Our results highlight the complexities associated with FeLV diagnosis, particularly
in environments with acute infections, in which some cats are in the initial phase of FeLV infection and
when the host–virus equilibrium has not yet been established [17,35,47]. Our results also highlight the
need for considering a range of diagnostic testing methodologies and for repeated testing to accurately
determine an individual cat’s FeLV infection status, a process which can be difficult in clinical practice.
5. Conclusions
Despite the reported decrease in the prevalence of FeLV infection in pet cats living in Europe,
Australia, and the USA, the threat of regressive and progressive FeLV infections persists, with
regressive infections being more than four times as common as progressive infections in pet cats
in Australia. The extent of FeLV exposure in the owned feline population and the association
between FeLV infection and various diseases (e.g., lymphoma, cytopenias) is generally underestimated;
qPCR testing for FeLV provirus, qRT-PCR testing for vRNA, and testing for anti-FeLV NAb is not
commonly performed in clinical practice or population surveys. Understanding the role of regressive
infections in FeLV-associated disease and transmission, specifically in relation to the development of
lymphoma, and particularly in cats in which the virus is transcriptionally active, will require further
field investigations. It is notable that the prevalence of FeLV exposure in pet cats was more than four
times greater than the prevalence of FeLV infection in our study, suggesting a higher potential risk than
previously documented in Australia. Consequently, veterinarians should consider vaccinating any
FeLV-uninfected cat with outdoor access against FeLV, as well as any cats that are group-housed with
cats of unknown retroviral status, to reduce the risk of progressive FeLV infection developing, especially
in the first few years of a cat’s life. Rescue facilities that allow group-housing should be especially
vigilant about screening new arrivals for FeLV during an initial quarantine period, keeping cats in
isolation before co-mingling of animals is permitted. When investigating FeLV infection, utilisation of
a panel of different tests, and repeated testing, may be required to accurately categorise the infection as
regressive, progressive, or focal.
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